Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Adjunctive Therapy in Treatment-Resistant Depression
NCT04739865Phase 2Completed
- Sponsor
- COMPASS Pathways
- Start
- Aug 2020
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by COMPASS Pathways. Started Aug 2020; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04739865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739865.